Multiple sclerosis: Current knowledge and future outlook

European Neurology

Volumn 72, Issue 3-4, 2014, Pages 132-141

  Kamm, Christian P ^a,b   Uitdehaag, Bernard M ^a   Polman, Chris H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Diagnostic criteria; Epidemiology; Multiple sclerosis; Pathophysiology; Treatment of multiple sclerosis

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; TERIFLUNOMIDE; IMMUNOLOGIC FACTOR;

ARTICLE; DISEASE COURSE; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS; PATHOLOGY;

CENTRAL NERVOUS SYSTEM; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS;

EID: 84906020064     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000360528     Document Type: Article

References (50)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis (review). N Engl J Med 2000; 343: 938-952.
2. Confavreux C, Vukusic S: Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129: 606-616.
3. Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vécsei L, Milanov I: The epidemiology of multiple sclerosis in Europe (review). Eur J Neurol 2006; 13: 700-722.
4. Alonso A, Hernán MA: Temporal trends in the incidence of multiple sclerosis: a systematic review (review). Neurology 2008; 71: 129-135.
5. Koch-Henriksen N, Sørensen PS: The changing demographic pattern of multiple sclerosis epidemiology (review). Lancet Neurol 2010; 9: 520-532.
6. Evans C, Beland SG, Kulaga S, Wolfson C, Kingwell E, Marriott J, Koch M, Makhani N, Morrow S, Fisk J, Dykeman J, Jetté N, Pringsheim T, Marrie RA: Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. Neuroepidemiology 2013; 40: 195-210.
7. Grytten Torkildsen N, Lie SA, Aarseth JH, Nyland H, Myhr KM: Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult Scler 2008; 14: 1191-1198.
8. Ascherio A, Munger KL, Simon KC: Vitamin D and multiple sclerosis. Lancet Neurol 2010; 9: 599-612.
9. Wingerchuk DM: Smoking: effects on multiple sclerosis susceptibility and disease progression. Ther Adv Neurol Disord 2012; 5: 13-22.
10. Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T: Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010; 74: 1041-1047.
11. Ascherio A, Munger KL: Environmental risk factors for multiple sclerosis. Part I. The role of infection (review). Ann Neurol 2007; 61: 288-299.
12. Berer K, Mues M, Koutrolos M, Rasbi ZA, Boziki M, Johner C, Wekerle H, Krishnamoorthy G: Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011; 479: 538-541.
13. Elian M, Nightingale S, Dean G: Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa and the West Indies. J Neurol Neurosurg Psychiatry 1990; 53: 906-911.
14. Willer CJ, Dyment DA, Sadovnick AD, Rothwell PM, Murray TJ, Ebers GC; Canadian Collaborative Study Group: Timing of birth and risk of multiple sclerosis: population based study. BMJ 2005; 330: 120.
15. Robertson NP, Fraser M, Deans J, Clayton D, Walker N, Compston DA: Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain 1996; 119: 449-455.
16. Hansen T, Skytthe A, Stenager E, Petersen HC, Brønnum-Hansen H, Kyvik KO: Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult Scler 2005; 11: 504-510.
17. Ebers GC, Sadovnick AD, Dyment DA, Yee IM, Willer CJ, Risch N: Parent-of-origin effect in multiple sclerosis: observations in halfsiblings. Lancet 2004; 363: 1773-1774.
18. Svenson LW, Warren S, Warren KG, Metz LM, Patten SB, Schopflocher DP: Prevalence of multiple sclerosis in First Nations people of Alberta. Can J Neurol Sci 2007; 34: 175-180.
19. Williamson DM, Henry JP, Schiffer R, Wagner L: Prevalence of multiple sclerosis in 19 Texas counties, 1998-2000. J Environ Health 2007; 69: 41-55.
20. Gourraud PA, Harbo HF, Hauser SL, Baranzini SE: The genetics of multiple sclerosis: an up-to-date review. Immunol Rev 2012; 248: 87-103.
21. Lin R, Charlesworth J, van der Mei I, Taylor BV: The genetics of multiple sclerosis (review). Pract Neurol 2012; 12: 279-288.
22. Lassmann H, Brück W, Lucchinetti CF: The immunopathology of multiple sclerosis: an overview (review). Brain Pathol 2007; 17: 210-218.
23. Lassmann H, Brück W, Lucchinetti C: Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy (review). Trends Mol Med 2001; 7: 115-121.
24. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Brück W, Parisi JE, Scheithauer BW, Giannini C, Weigand SD, Mandrekar J, Ransohoff RM: Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011; 365: 2188-2197.
25. Stys PK, Zamponi GW, van Minnen J, Geurts JJ: Will the real multiple sclerosis please stand up (review)? Nat Rev Neurosci 2012; 13: 507-514, erratum 2012; 13: 597.
26. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
27. Lublin FD, Reingold SC: Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.
28. Vukusic S, Confavreux C: Natural history of multiple sclerosis: risk factors and prognostic indicators (review). Curr Opin Neurol 2007; 20: 269-274.
29. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria (review). Ann Neurol 2011; 69: 292-302.
30. Burton JM, O'Connor PW, Hohol M, Beyene J: Oral versus intravenous steroids for treatment of relapses in multiple sclerosis (review). Cochrane Database Syst Rev 2012; 12:CD006921.
31. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A: Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (review). Neurology 2011; 76: 294-300.
32. McGraw CA, Lublin FD: Interferon beta and glatiramer acetate therapy. Neurotherapeutics 2013; 10: 2-18.
33. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group: Randomized trial of oral teriflunomide for relapsing multiple sclerosis. TEMSO Trial Group. N Engl J Med 2011; 365: 1293-1303.
34. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators: A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
35. Baldwin KJ, Hogg JP: Progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Curr Opin Neurol 2013; 26: 318-323.
36. Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, Ravnborg M, Hauser SL, Rudick RA, Weiner HL, O'Connor PW, King J, Radue EW, Yousry T, Major EO, Clifford DB: Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring (review). Lancet Neurol 2007; 6: 431-441.
37. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group: A placebo-controlled trial or oral fingolimod in relapsing remitting multiple sclerosis. N Engl J Med 2010; 362: 387-401.
38. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
39. Espinosa PS, Berger JR: Delayed fingolimodassociated asystole. Mult Scler 2011; 17: 1387-1389.
40. Lindsey JW, Haden-Pinneri K, Memon NB, Buja LM: Sudden unexpected death on fingolimod. Mult Scler 2012; 18: 1507-1508.
41. Hartung HP, Gonsette R, K?nig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T; Mitoxantrone in Multiple Sclerosis Study Group (MIMS): Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-2025.
42. Neuhaus O, Kieseier BC, Hartung HP: Therapeutic role of mitoxantrone in multiple sclerosis (review). Pharmacol Ther 2006; 109: 198-209.
43. de Sa JC, Airas L, Bartholome E, Grigoriadis N, Mattle H, Oreja-Guevara C, O'Riordan J, Sellebjerg F, Stankoff B, Vass K, Walczak A, Wiendl H, Kieseier BC: Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord 2011; 4: 139-168.
44. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators: Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098-1107, erratum p 2362.
45. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I Investigators: Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380: 1819-1828.
46. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II Investigators: Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380: 1829-1839.
47. Katsavos S, Anagnostouli M: Biomarkers in multiple sclerosis: an up-to-date overview. Mult Scler Int 2013; 2013: 340508.
48. Van der Walt A, Butzkueven H, Kolbe S, Marriott M, Alexandrou E, Gresle M, Egan G, Kilpatrick T: Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade. Pharmacol Ther 2010; 126: 82-93.
49. Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M; ALLEGRO Study Group: Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012; 366: 1000-1009.
50. Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G; SELECT study investigators: Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013; 381: 2167-2175.